Hung Amos C, Wang Yen-Yun, Lee Kun-Tsung, Chiang Hung-Hsing, Chen Yuk-Kwan, Du Je-Kang, Chen Chun-Ming, Chen Michael Yuanchien, Chen Kwei-Jing, Hu Stephen Chu-Sung, Yuan Shyng-Shiou F
Translational Research Center, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C.
Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan, R.O.C.
Oncol Lett. 2021 Nov;22(5):774. doi: 10.3892/ol.2021.13035. Epub 2021 Sep 10.
Esophageal cancer is one of the most common malignancies and leading cause of cancer-associated mortality worldwide. However, the molecular mechanisms underlying esophageal cancer progression and the development of clinical tools for effective diagnosis remain unclear. Resistin, which was originally identified as an adipose tissue-secretory factor, has been associated with obesity-related diseases, including certain types of cancer. Thus, the present study aimed to investigate the expression levels of resistin in tissue and serum specimens from patients with esophageal squamous cell carcinoma (ESCC) to determine the potential biological effects of resistin on ESCC cells. The results demonstrated that both tissue and serum resistin levels were significantly lower in patients with ESCC compared with healthy controls. In addition, resistin expression was positively associated with the body mass index of patients with ESCC. studies revealed that resistin inhibited the migratory ability of ESCC cells, while having no effect on ESCC cell proliferation. Taken together, these results suggest that resistin may have the potential to be developed into a clinical marker for ESCC. However, further studies are required to investigate resistin receptor expression and determine the potential involvement of resistin-associated biological pathways, which may provide insight for future development of targeted therapies for resistin-mediated ESCC.
食管癌是全球最常见的恶性肿瘤之一，也是癌症相关死亡的主要原因。然而，食管癌进展的分子机制以及有效诊断的临床工具的开发仍不清楚。抵抗素最初被鉴定为一种脂肪组织分泌因子，已与包括某些类型癌症在内的肥胖相关疾病有关。因此，本研究旨在调查食管鳞状细胞癌（ESCC）患者组织和血清标本中抵抗素的表达水平，以确定抵抗素对ESCC细胞的潜在生物学作用。结果表明，与健康对照相比，ESCC患者的组织和血清抵抗素水平均显著降低。此外，抵抗素表达与ESCC患者的体重指数呈正相关。研究表明，抵抗素抑制ESCC细胞的迁移能力，而对ESCC细胞增殖没有影响。综上所述，这些结果表明抵抗素可能有潜力被开发成为ESCC的临床标志物。然而，需要进一步研究来调查抵抗素受体的表达，并确定抵抗素相关生物学途径的潜在参与情况，这可能为未来针对抵抗素介导的ESCC的靶向治疗的开发提供思路。
